



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/269233/2016

## European Medicines Agency decision

P/0144/2016

of 23 May 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral for human recombinant IgG1 monoclonal antibody targeting fibroblast growth factor 23 (KRN23) (EMEA-001659-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**



# European Medicines Agency decision

P/0144/2016

of 23 May 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral for human recombinant IgG1 monoclonal antibody targeting fibroblast growth factor 23 (KRN23) (EMA-001659-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Ultragenyx Pharmaceutical Inc. on 6 June 2015 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 April 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for human recombinant IgG1 monoclonal antibody targeting fibroblast growth factor 23 (KRN23), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for human recombinant IgG1 monoclonal antibody targeting fibroblast growth factor 23 (KRN23), solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

This decision is addressed to Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, 94949 - Novato, United States of America.

Done at London, 23 May 2016

For the European Medicines Agency  
Zaïde Frias  
Head of Division  
Human Medicines Research and Development Support  
(Signature on file)

EMA/PDCO/22980/2016

London, 1 April 2016

## Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-001659-PIP01-15

### Scope of the application

**Active substance(s):**

Human recombinant IgG1 monoclonal antibody targeting fibroblast growth factor 23 (KRN23)

**Condition(s):**

Treatment of X-linked hypophosphataemia

**Pharmaceutical form(s):**

Solution for injection

**Route(s) of administration:**

Subcutaneous use

**Name / corporate name of the PIP applicant:**

Ultragenyx Pharmaceutical Inc.

### Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Ultragenyx Pharmaceutical Inc. submitted for agreement to the European Medicines Agency on 6 June 2015 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 14 July 2015.

Supplementary information was provided by the applicant on 4 January 2016. The applicant proposed modifications to the paediatric investigation plan.

## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

## 1. Waiver

Not applicable.

## 2. Paediatric investigation plan

### 2.1. Condition:

Treatment of X-linked hypophosphataemia

#### 2.1.1. Indication(s) targeted by the PIP

Treatment of X-linked hypophosphataemia

#### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

#### 2.1.3. Pharmaceutical form(s)

Solution for injection

#### 2.1.4. Measures

| Area                    | Number of measures | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Quality-related studies | 0                  | Not applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Non-clinical studies    | 0                  | Not applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Clinical studies        | 4                  | <p><b>Study 1 (UX023-CL201)</b></p> <p>Open-label, randomised, multicentre, multiple dose, uncontrolled study to evaluate pharmacokinetics, safety, activity and quality of life of human recombinant IgG1 monoclonal antibody targeting fibroblast growth factor 23 (KRN23) in children from 5 years to less than 13 years of age with X-linked hypophosphataemia.</p> <p><b>Study 2 (UX023-CL301)</b></p> <p>Open-label, randomised, multicentre, active controlled study to evaluate pharmacokinetics, safety, efficacy and quality of life of KRN23 compared to oral phosphate/active vitamin D therapy in children from 1 year to less than 13 years of age at the start of the study with X-linked hypophosphataemia.</p> |

| Area                                            | Number of measures | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 |                    | <p><b>Study 3 (UX023-CL207)</b></p> <p>Open-label, multicentre, uncontrolled study to evaluate safety, pharmacodynamics and activity of KRN23 in children from birth to less than 1 year of age with X-linked hypophosphataemia.</p> <p><b>Study 4 (UX023-CL205)</b></p> <p>Open-label, multicentre, uncontrolled study to evaluate pharmacodynamics, safety and activity of KRN23 in children from 1 year to less than 5 years of age with X-linked hypophosphataemia.</p> |
| Extrapolation, modelling and simulation studies | 0                  | Not applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Other studies                                   | 0                  | Not applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Other measures                                  | 0                  | Not applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

### 3. Follow-up, completion and deferral of PIP

|                                                                                       |                   |
|---------------------------------------------------------------------------------------|-------------------|
| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | Yes               |
| Date of completion of the paediatric investigation plan:                              | By September 2020 |
| Deferral for one or more measures contained in the paediatric investigation plan:     | Yes               |